The GARDEL study ( Global AntiRetroviral Design Encompassing Lopinavir/r and Lamivudine vs LPV/r based standard therapy ) is a 48 week , phase 3 , randomised , controlled , open-label , non-inferiority trial in antiretroviral-therapy-naive adults ( age 18 years ) with documented HIV-1 RNA viral load of at least 1000 copies per mL .